These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15171791)

  • 1. Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
    Kramer BW; Götz R; Rapp UR
    BMC Cancer; 2004 Jun; 4():24. PubMed ID: 15171791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L; Trail PA; Taylor I; Wilhelm SM
    Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAG-1 haplo-insufficiency impairs lung tumorigenesis.
    Götz R; Kramer BW; Camarero G; Rapp UR
    BMC Cancer; 2004 Nov; 4():85. PubMed ID: 15560850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R; Piperdi S; Gorlick R
    Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
    Lee M
    Biochem Biophys Res Commun; 2006 Nov; 350(2):450-6. PubMed ID: 17010316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raf pathway inhibitors in oncology.
    Bollag G; Freeman S; Lyons JF; Post LE
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1436-41. PubMed ID: 14763129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of c-Raf-1: therapeutic implications.
    Beeram M; Patnaik A; Rowinsky EK
    Clin Adv Hematol Oncol; 2003 Aug; 1(8):476-81. PubMed ID: 16258435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf.
    Mercer K; Chiloeches A; Hüser M; Kiernan M; Marais R; Pritchard C
    Oncogene; 2002 Jan; 21(3):347-55. PubMed ID: 11821947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein.
    Kerkhoff E; Fedorov LM; Siefken R; Walter AO; Papadopoulos T; Rapp UR
    Cell Growth Differ; 2000 Apr; 11(4):185-90. PubMed ID: 10775035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NBS1 is required for IGF-1 induced cellular proliferation through the Ras/Raf/MEK/ERK cascade.
    Hematulin A; Sagan D; Eckardt-Schupp F; Moertl S
    Cell Signal; 2008 Dec; 20(12):2276-85. PubMed ID: 18793719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
    Kogut MH; Genovese KJ; He H
    Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sphingomyelinase decreases type II collagen expression in bovine articular cartilage chondrocytes via the ERK signaling pathway.
    Gilbert SJ; Blain EJ; Duance VC; Mason DJ
    Arthritis Rheum; 2008 Jan; 58(1):209-20. PubMed ID: 18163502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C; Settleman J
    Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
    Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
    Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.